Patients Discontinuing Weight-Loss Jabs Gain Back Pounds at a Quadrupled Rate Than Dieters

New research reveals that patients who come off blockbuster slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt traditional lifestyle plans.

Research printed in a major health publication demonstrates that while obese individuals can lose about a fifth of their total mass while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month after stopping.

"Individuals using these drugs should be cognizant of the risk of fast rebound weight gain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.

This pace of regain suggests a return to starting weight in about a year and a half.

Comparing Therapies

The analysis, which looked at 37 of trials involving over 9,000 of patients, compared the results of the injectable medications with conventional dieting.

Scientists note that people who shed pounds through diet and exercise generally have a less rapid creep back—around 100 grams monthly—after stopping.

Understanding the Fast Rebound

Experts suggest the mode of action of the jabs is key to understanding the amplified weight return.

These medications mimic a body's own chemical called GLP-1, which helps regulate appetite.

"Artificially providing the hormone concentrations several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.

"Stopping of this hormone supplement means hunger is uncontrolled, making excessive eating much more probable."

An Ongoing Issue?

The NHS recommend the injections for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.

A number of clinicians argue that, due to the significant potential of relapse, the therapy should be considered long-term.

This opinion is reinforced by drug manufacturers, who say that the findings "emphasize the long-term nature of obesity," similar to managing conditions like hypertension.

Patient Accounts

Users who have stopped the jabs explain a powerful resurgence of cravings.

"I experienced something flipping and you become extremely hungry," recalled one woman.

This difficulty is worsened if users have not adopted lasting lifestyle or habit modifications during treatment.

Significant Use

Recent estimates suggest that millions of adults in the UK have used weight-loss jabs in the past year, with interest being substantial.

• Adoption is more common among women compared to men.
• The 40s and 50s demographic shows the greatest level of interest.
• Many access the drugs through private healthcare rather than the NHS.

Ultimately, researchers stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone solution and long-term success hinges on ongoing lifestyle changes.